<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Infectious Disease]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/infectious-disease</link>
    <description><![CDATA[Infectious Disease]]></description>
    <pubDate>Tue, 09 Jun 2026 02:39:59 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/respiratory-syncytial-virus-rsv-infections-drugs-in-development-by-stages</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.<br><br>Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of developme...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-228276"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Mon, 26 Dec 2022 14:24:58 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Bacterial Sepsis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/bacterial-sepsis-drugs-in-development-by-stages-target-moa-roa-molecule</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Bacterial Sepsis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Bacterial Sepsis pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Bacterial Sepsis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/univer...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227207"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Polyomavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/polyomavirus-infections-drugs-in-development-by-stages-target-moa-roa-m</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Polyomavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Polyomavirus Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Polyomavirus Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary data...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-227305"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 13 Jul 2022 12:37:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/staphylococcus-aureus-infections-drugs-in-development-by-stages-target-mo</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Staphylococcus Aureus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Staphylococcus Aureus Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Staphylococcus Aureus Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226734"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 14:45:37 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Simplexvirus (HSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/simplexvirus-hsv-infections-drugs-in-development-by-stages-target-moa</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Simplexvirus (HSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Simplexvirus (HSV) Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226774"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 14:45:37 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Human Parainfluenza Virus 3 Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/human-parainfluenza-virus-3-infections-drugs-in-development-by-stages-targ</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Human Parainfluenza Virus 3 Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Human Parainfluenza Virus 3 Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Human Parainfluenza Virus 3 Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced fr...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226788"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 14:45:37 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Chlamydia Trachomatis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/chlamydia-trachomatis-infections-drugs-in-development-by-stages-target-mo</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Chlamydia Trachomatis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Chlamydia Trachomatis Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Chlamydia Trachomatis Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226660"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 13:59:20 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Community-Acquired Bacterial Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/community-acquired-bacterial-pneumonia-drugs-in-development-by-stages-targ</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Community-Acquired Bacterial Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Community-Acquired Bacterial Pneumonia pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Community-Acquired Bacterial Pneumonia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced fr...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226682"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 13:59:20 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Burkholderia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players]]></title>
      <link>https://www.leadingmarketresearch.com/burkholderia-infections-drugs-in-development-by-stages-target-moa-roa-m</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Burkholderia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Burkholderia Infections pipeline landscape.<br><br>The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.<br><br>The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<br><br>The report is built using data and information sourced from Global Markets Direct’s proprietary data...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226644"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Jul 2022 13:47:50 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Marburgvirus Infections (Marburg Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update]]></title>
      <link>https://www.leadingmarketresearch.com/marburgvirus-infections-marburg-hemorrhagic-fever-drugs-in-development-by</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.<br><br>Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss. <br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-226466"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 17 Jun 2022 15:11:14 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Global Infection Control Market by Product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks], End User (Hospitals, Pharmaceutical Companies) - Global Forecast to 2027]]></title>
      <link>https://www.leadingmarketresearch.com/global-infection-control-market-by-product-sterilization-steam-hydrogen</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">The global infection control market is expected to grow at a CAGR of ~3.3% from 2021 to reach ~54.8 billion by 2027. The growth is primarily attributed to prevalence of infectious diseases, rising geriatric population, rising focus on sterilization, technological advancements, expansion of pharmaceutical companies and medical devices in emerging economies, increasing number of surgical procedures and rising outsourcing of sterilization services. However, safety aspect of reprocessed instruments can hinder the growth of this market. COVID-19 has offered significant growth opportunity to the market players. 

By Product & Services: Protective barrier segment dominated the infection control market in 2020 
Based on products & services, infection control market is segmented into sterilization products & services, cleaning & disinfection products, protective barriers, endoscope reprossing products and other infection control products. Protective barrier segment accounted for the largest share of infection control market. The largest share of this market is mainly due to significant rise a...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-225165"><span class="price">$3,400.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Wed, 11 May 2022 11:50:02 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/burkholderia-pseudomallei-infections-melioidosis-infectious-disease-d</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections - Drugs In Development, 2021, provides an overview of the Burkholderia pseudomallei Infections (Infectious Disease) pipeline landscape.Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type....





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221645"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Escherichia coli Infections (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/escherichia-coli-infections-infectious-disease-drugs-in-development-20</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Drugs In Development, 2021, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Drugs In Devel...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221646"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Tularaemia (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/tularaemia-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Drugs In Development, 2021, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechan...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221647"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Diphtheria (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/diphtheria-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Drugs In Development, 2021, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221648"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/vancomycin-resistant-enterococcus-faecium-infections-infectious-disease</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2021, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline gu...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221649"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/methicillin-resistant-staphylococcus-aureus-mrsa-infections-infectious-d</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Methicillin-Resistant Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Methicillin-Resistant S...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221650"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/methicillin-susceptible-staphylococcus-aureus-mssa-infections-infectious</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221651"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Impetigo (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/impetigo-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Drugs In Development, 2021, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Impetigo - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221652"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Tuberculosis (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/tuberculosis-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Drugs In Development, 2021, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the d...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221653"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Aspergillosis (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/aspergillosis-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Drugs In Development, 2021, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221654"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cryptosporidiosis (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/cryptosporidiosis-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Drugs In Development, 2021, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest ne...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221655"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Malaria (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/malaria-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Drugs In Development, 2021, provides an overview of the Malaria (Infectious Disease) pipeline landscape.Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Malaria - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The g...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221656"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Leishmaniasis (Kala-Azar) (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/leishmaniasis-kala-azar-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis - Drugs In Development, 2021, provides an overview of the Leishmaniasis (Infectious Disease) pipeline landscape.Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Leishmaniasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Leishmaniasis (Infectious...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221657"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Hepatitis B (Infectious Disease) - Drugs in Development, 2021]]></title>
      <link>https://www.leadingmarketresearch.com/hepatitis-b-infectious-disease-drugs-in-development-2021</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct&#039;s latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.<br><br>Report Highlights<br><br>Global Markets Direct&#039;s Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-221658"><span class="price">$2,500.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Tue, 12 Oct 2021 15:07:55 +0000</pubDate>
    </item>
  </channel>
</rss>
